Clinical Trials on Respiratory Syncytial Virus (RSV)

Total 10959 results

GlaxoSmithKline

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Respiratory Syncytial Virus Infections

Finland, Spain, United Kingdom, United States, Thailand, Brazil, Canada, Panama, Italy, Colombia, Mexico, Poland, Turkey
GlaxoSmithKline

Completed

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Respiratory Syncytial Virus Infections

Japan
Pontificia Universidad Catolica de Chile
Millennium Institute on Immunology and Immunotherapy; Comisión Nacional de...

Completed

A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV (EVA-VRS01)

Respiratory Syncytial Virus Infections

Chile
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Pfizer

Completed

Pharmacokinetics and Safety of RV521 Formulations (C19007)

Respiratory Syncytial Virus Infections

United Kingdom
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain
Bavarian Nordic

Withdrawn

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Respiratory Syncytial Virus Infections
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
Alnylam Pharmaceuticals

Completed

Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

United States, Australia, Austria, Canada, France, Germany
Alnylam Pharmaceuticals

Completed

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

United States, Australia
Bavarian Nordic

Completed

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Respiratory Syncytial Virus Infections

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

Respiratory Syncytial Virus Infections

Japan
Ark Biosciences Inc.

Completed

Safety, Tolerability and PK Study of AK0529 in Healthy Human

Respiratory Syncytial Virus Infections

Australia
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
West Penn Allegheny Health System
American Academy of Allergy, Asthma, and Immunology

Completed

Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly

Respiratory Syncytial Virus Infections

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

Respiratory Syncytial Virus Infections

United States, Finland, Ghana, Honduras, India, Spain, Thailand
Daiichi Sankyo Co., Ltd.

Completed

Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects

Respiratory Syncytial Virus Infections

Japan
Janssen Vaccines & Prevention B.V.

Terminated

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

United States
GlaxoSmithKline

Recruiting

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Spain, Belgium, Korea, Republic of, France, Canada, Finland, Taiwan, Thailand, Brazil, India, New Zealand, Germany, South Africa, Colombia, Panama, Philippines, Argentina, Bangladesh, Dominican Republic and more
Pfizer

Completed

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Terminated

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

Respiratory Syncytial Virus Infections

United States, Australia, France, Finland, Taiwan, Spain, Philippines, Mexico, Belgium, Italy, Panama, New Zealand, Thailand, Brazil, Canada, India, Colombia, Korea, Republic of, United Kingdom, South Africa, Argentina, Bangladesh, Dominican... and more
GlaxoSmithKline

Terminated

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Respiratory Syncytial Virus Infections

United States, Spain, Brazil, Canada, Finland, India, Italy, Panama, South Africa
GlaxoSmithKline

Active, not recruiting

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Finland, Germany, Japan, Taiwan
Bavarian Nordic

Completed

MVA-BN-RSV Vaccine Trial

Respiratory Syncytial Virus Infections

United States, Germany
GlaxoSmithKline

Completed

A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance (PEPNI)

Respiratory Syncytial Virus Infections

Philippines, Mexico, Thailand, Brazil, Colombia, Panama, South Africa, Argentina, Bangladesh, Malaysia
GlaxoSmithKline

Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Respiratory Syncytial Virus Infections

United States, Belgium
Janssen Research & Development, LLC

Completed

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States, Taiwan, Japan, Korea, Republic of, France, Mexico, Brazil, Sweden, Argentina, Ukraine, Canada, Spain, Germany, Poland, Belgium, Russian Federation, South Africa, Australia, Bulgaria
GlaxoSmithKline

Withdrawn

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Completed

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus Infections

United States
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
GlaxoSmithKline

Completed

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Respiratory Syncytial Virus Infections

Germany, Estonia, Belgium, France
National Institute of Allergy and Infectious Diseases...

Completed

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

Respiratory Syncytial Virus Infections

Belgium
Alios Biopharma Inc.

Completed

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

Respiratory Syncytial Virus Infections

France
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Respivert Ltd

Completed

RV568 - Viral Challenge With RSV

Respiratory Syncytial Virus Infections

United Kingdom
Alnylam Pharmaceuticals

Completed

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States
M.D. Anderson Cancer Center

Completed

Respiratory Syncytial Virus - RSV Protocol

Cancer | Acute Leukemia | Respiratory Syncytial Virus Infections | Bone Marrow Transplant Infection | Infection in Marrow Transplant Recipients | Respiratory Syncytial Virus Pneumonia

United States
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
ReiThera Srl

Completed

RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.

Respiratory Syncytial Virus Infections

United Kingdom
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

United States, Canada, Japan, Germany, Australia, South Africa
Ark Biosciences Inc.

Unknown

Anti-RSV Study in Chinese Patients (ASCENT) (ASCENT)

Respiratory Syncytial Virus Infections

China
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
Biota Scientific Management Pty Ltd

Completed

Safety Study of Oral BTA9881 to Treat RSV Infection

Respiratory Syncytial Virus Infections

Australia
Janssen Sciences Ireland UC

Terminated

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA)

Respiratory Syncytial Virus Infections

United States, Belgium, Taiwan, Israel, Japan, Argentina, Malaysia, Korea, Republic of, Netherlands, Spain, Australia, Italy, Brazil, France, United Kingdom, Sweden, Bulgaria
Ark Biosciences Inc.

Terminated

A Study of AK0529 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

Australia

Clinical Trials on Respiratory Syncytial Virus (RSV)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations